136 related articles for article (PubMed ID: 26603897)
1. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.
Feng Y; Pinkerton AB; Hulea L; Zhang T; Davies MA; Grotegut S; Cheli Y; Yin H; Lau E; Kim H; De SK; Barile E; Pellecchia M; Bosenberg M; Li JL; James B; Hassig CA; Brown KM; Topisirovic I; Ronai ZA
Cancer Res; 2015 Dec; 75(24):5211-8. PubMed ID: 26603897
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
[TBL] [Abstract][Full Text] [Related]
3. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
[TBL] [Abstract][Full Text] [Related]
4. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
5. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.
Zindy P; Bergé Y; Allal B; Filleron T; Pierredon S; Cammas A; Beck S; Mhamdi L; Fan L; Favre G; Delord JP; Roché H; Dalenc F; Lacroix-Triki M; Vagner S
Cancer Res; 2011 Jun; 71(12):4068-73. PubMed ID: 21498638
[TBL] [Abstract][Full Text] [Related]
6. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
Pelletier J; Graff J; Ruggero D; Sonenberg N
Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
[TBL] [Abstract][Full Text] [Related]
7. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
Wang T; Xiao M; Ge Y; Krepler C; Belser E; Lopez-Coral A; Xu X; Zhang G; Azuma R; Liu Q; Liu R; Li L; Amaravadi RK; Xu W; Karakousis G; Gangadhar TC; Schuchter LM; Lieu M; Khare S; Halloran MB; Herlyn M; Kaufman RE
Clin Cancer Res; 2015 Apr; 21(7):1652-64. PubMed ID: 25617424
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppression by small molecule inhibitors of translation initiation.
Chen L; Aktas BH; Wang Y; He X; Sahoo R; Zhang N; Denoyelle S; Kabha E; Yang H; Freedman RY; Supko JG; Chorev M; Wagner G; Halperin JA
Oncotarget; 2012 Aug; 3(8):869-81. PubMed ID: 22935625
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
Malka-Mahieu H; Newman M; Désaubry L; Robert C; Vagner S
Clin Cancer Res; 2017 Jan; 23(1):21-25. PubMed ID: 27789529
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of eIF4F complex loading inhibits the survival of malignant glioma.
Dong QF; Yan ZF; Li PQ; Yang X; Huo JL; Zhen HN
Oncol Rep; 2018 Oct; 40(4):2399-2407. PubMed ID: 30066885
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex.
Feng Y; Grotegut S; Jovanovic P; Gandin V; Olson SH; Murad R; Beall A; Colayco S; De-Jesus P; Chanda S; English BP; Singer RH; Jackson M; Topisirovic I; Ronai ZA
Front Pharmacol; 2022; 13():1029093. PubMed ID: 36532738
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
13. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
Rotolo S; Diotti R; Gordon RE; Qiao RF; Yao Z; Phelps RG; Dong J
Int J Cancer; 2005 May; 115(1):164-9. PubMed ID: 15657897
[TBL] [Abstract][Full Text] [Related]
14. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
15. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
16. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.
Schön M; Wienrich BG; Kneitz S; Sennefelder H; Amschler K; Vöhringer V; Weber O; Stiewe T; Ziegelbauer K; Schön MP
J Natl Cancer Inst; 2008 Jun; 100(12):862-75. PubMed ID: 18544741
[TBL] [Abstract][Full Text] [Related]
17. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas.
de Groot E; Varghese S; Tan L; Knighton B; Sobieski M; Nguyen N; Park YS; Powell R; Lorenzi PL; Zheng B; Stephan C; Gopal YNV
Cancer Metab; 2022 Feb; 10(1):6. PubMed ID: 35193687
[TBL] [Abstract][Full Text] [Related]
19. Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
Joyce CE; Yanez AG; Mori A; Yoda A; Carroll JS; Novina CD
Cancer Res; 2017 Feb; 77(3):613-622. PubMed ID: 27879264
[TBL] [Abstract][Full Text] [Related]
20. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]